Actively Recruiting
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
Led by Chongqing University Cancer Hospital · Updated on 2023-04-11
120
Participants Needed
1
Research Sites
461 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.
CONDITIONS
Official Title
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cervical cancer stage IIb to IVa with squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma
- Completed concurrent chemoradiation therapy with radiation dose A point 85Gy (+/-10%), B point 50Gy (+/-10%), and platinum-containing chemotherapy (cisplatin or carboplatin)
- MRI within 4 weeks after chemoradiation shows residual lesions (non-lymph node lesion ≥10mm or lymph node shortest diameter ≥15mm)
- ECOG performance status less than 2
- Expected survival longer than six months
- Hemoglobin ≥70 g/L, white blood cell count ≥3.5 x 10^9/L, absolute neutrophil count ≥1.5 x 10^9/L, platelet count ≥80 x 10^9/L
- ALT and AST levels ≤2 times upper limit of normal, serum creatinine ≤1.5 times upper limit of normal
- Negative serum or urine pregnancy test within 7 days before enrollment for women of childbearing age who agree to use contraception during the trial
You will not qualify if you...
- Active or uncontrolled severe infection
- Liver cirrhosis or decompensated liver disease
- History of immune deficiency, including HIV positive or congenital immunodeficiency
- Unable to tolerate chemotherapy due to chronic renal insufficiency or renal failure
- Current or past other malignant tumors
- History of myocardial infarction, severe arrhythmia, or NYHA class 2 or higher congestive heart failure
- Previous targeted therapy or pelvic artery embolization
- Artery-venous thrombosis within past 6 months
- Autoimmune diseases
- Complications requiring drugs that may cause liver or kidney injury
- Disease progression after chemoradiation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
Research Team
D
Dongling Zou, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here